Abbratech provides custom recombinant antibody discovery and development services using EPIVOLVE technology, which enables precise antibody engineering at nearly amino acid resolution. The company addresses the challenges of slow and inconsistent antibody development by producing high-affinity antibodies tailored to specific antigen sites, regardless of their immunogenicity or modification.
Funding
Funding not disclosed
Founders
Product
Problem
Current antibody development methods are often slow, inconsistent, and struggle to generate antibodies that bind to specific, desired sites on an antigen, especially when the target site has low immunogenicity or unique modifications. This can limit the development of effective diagnostics and therapeutics.
Solution
Abbratech offers custom recombinant antibody discovery and development services using its EPIVOLVE technology. This platform enables precise antibody engineering at near-amino acid resolution, allowing for the generation of high-affinity antibodies tailored to specific antigen sites, regardless of immunogenicity, tolerance, or modification. By combining in vivo and in vitro methods, including phage display and small animal B-cell cloning, Abbratech addresses the need for affinity reagents against difficult targets in the research, pharmaceutical, and diagnostic markets. The EPIVOLVE technology leverages advancements in human genome sequencing and antibody engineering to produce highly specific recombinant antibodies with targeted precision.
Target Audience
Abbratech's primary customers are researchers, pharmaceutical companies, and diagnostic firms seeking custom antibody development services for challenging targets.
Features
- EPIVOLVE technology for precise antibody engineering at near-amino acid resolution
- Custom antibody development services tailored to specific antigen sites
- Utilization of both phage display and small animal B-cell cloning methods
- High-affinity and highly specific recombinant antibody production
- Expertise in developing antibodies against difficult targets with low immunogenicity or unique modifications